Webinar
New Ways to Discover Novel Peptide Therapeutics
June 06, 2024 03:00 PM CET
This webinar focuses on challenges in peptide drug discovery and how Biosynth’s CLIPS (Chemical Linkage of Peptides onto Scaffolds) peptide phage display technology tackles these challenges.
Furthermore, peptide lead optimization, either for binding activity/selectivity or drug-like properties, will be discussed as well as the challenges and possible solutions related to synthesis & manufacturing both at the R&D- and GMP-level.
Webinar learning objectives:
- How discovery of cyclic peptides via phage display works.
- How lead optimization of cyclic peptide leads can be achieved.
- Understanding of the main challenges to be solved in this rapidly evolving field.
Peter Timmerman
Peter Timmerman is Head of Peptide Science at Biosynth and responsible for scientific developments and further advances for Biosynth’s Peptide Discovery Platform.
He is inventor of the CLIPS™ technology and held a chair as Professor (by special appointment) in Protein Mimetic Chemistry at the University of Amsterdam (UvA) from 2007 to 2022.
Sangram Kale
Dr. Sangram Kale is Head of Peptide Discovery at Biosynth, leading global peptide discovery projects.
Sangram earned his PhD in Chemistry in 2013 with focus on peptide and medicinal chemistry from University of Pune and National Chemical Laboratory, Pune, India.
Sangram then pursued his post doc studies with Prof. Christian Heinis at EPFL, Switzerland where he developed bibridged peptide phage display technology.
Prior to start his industrial career at Biosynth (former Pepscan) Sangram worked as Scientific staff at Max Plank Institute for Medical Research, Heidelberg, Germany.